ESR1 PvuII (rs2234693 T>C) polymorphism and cancer susceptibility: Evidence from 80 studies

Abstract

Emerging epidemiological researches have been performed to assess the association of ESR1 PvuII (rs2234693 T>C) polymorphism with the risk of cancer, yet with conflicting conclusions. Therefore, this updated meta-analysis was performed to make a more accurate evaluation of such relationship. We adopted EMBASE, PubMed, CNKI, and WANFANG database to search relevant literature before January 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were employed to estimate the relationship strengths. In final, 80 studies (69 publications) involving 26428 cases and 43381 controls were enrolled. Our results failed to provide significant association between overall cancer risk and PvuII polymorphism under homozygous (TT vs. CC) and heterozygous (TT vs. CT) models. Statistically significant relationship was only observed for PvuII polymorphism in allele model T vs. C (OR=0.95, 95% CI=0.91-0.99). Stratification analysis by cancer type suggested that T genotype significantly decreased prostate cancer risk (TT vs. CC: OR=0.79, 95% CI=0.66-0.94; T vs. C: OR=0.89, 95% CI=0.82-0.98), Leiomyoma risk (T vs. C: OR=0.82, 95% CI=0.68-0.98), and HCC risk (TT vs. CC: OR=0.45, 95% CI=0.28-0.71; T vs. C: OR=0.67, 95% CI=0.47-0.95). Furthermore, significantly decreased risk was also found for Africans, population-based and hospital-based studies in the stratified analyses. These results suggest that ESR1 PvuII (rs2234693 T>C) polymorphism may only have little impact on cancer susceptibility. In the future, large-scale epidemical studies are warranted to verify these results.

O Estudo Da Miiase Bucal Em Pacientes Com Transtornos Mentais : Revisão De Literatura

“…These genetic polymorphisms investigated here were associated with a variety of phenotypes (MARUYAMA et al, 2000, YANG et al, 2014LIU et al, 2018;LUO et al, 2018). However, they were not associated with maxillary central incisors proportion in both studied populations.…”

Assessment of Estrogen Receptor Gene Polymorphism (T-397c Variant) in Patients With Premenstrual Syndrome

“…There are reports about its significance as the risk factor in the forming of cancer conditions -cancer of breast [8], endometrium [9], prostate [10], hepatocellular carcinoma [11], etc. However, the meta-analysis in EMBASE, PubMed, CNKI, and WANFANG systems, in which the literature data were collected till 2018, suggest that ESR1PvuII (rs2234693 T>C) polymorphism may only have little impact on cancer susceptibility [12].…”

Association between ESR1 rs2234693 single nucleotide polymorphism and uterine fibroids in Taiwanese premenopausal and postmenopausal women

“…We chose rs2234693 because it is associated with female reproduction and is one of the most commonly assessed ESR1 SNPs [40,49]. Genotyping experiments were performed by the National Center for Genome Medicine in Academia Sinica using a custom Affymetrix Axiom Genome-Wide Array Plate (Affymetrix Inc. Santa Clara, CA, USA) called TWB chip.…”

“…Single nucleotide polymorphisms (SNPs) play a key role in the effective prevention of diseases because they serve as disease markers that assist in the early identification of at-risk individuals [39]. For instance, ESR1 PvuII (rs2234693), a genetic variation caused by a nucleotide change from T to C (T > C) is the most studied variant of the ESR1 gene [22,[40][41][42]. It has been associated with an increased risk of UFs in Taiwanese [35], Black, and White American women [33], but not in German [43], Polish [42], Italian [44,45], Hispanic [33], and Iranian women [46].…”